| | | | |
CUSIP No. 357023100 | | | | Page 3 of 5 Pages |
This Amendment No. 7 to Schedule 13D (“Amendment No. 7”) amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission on August 11, 2021 (as amended by Amendment No. 1 to Schedule 13D filed on November 9, 2021, Amendment No. 2 to Schedule 13D filed on January 7, 2022, Amendment No. 3 to Schedule 13D filed on April 12, 2022, Amendment No. 4 to Schedule 13D filed on August 8, 2022, Amendment No. 5 to Schedule 13D filed on November 8, 2022, Amendment No. 6 to Schedule 13D filed on March 29, 2023, collectively, the “Original 13D”) and, collectively with this Amendment No. 7, the “Statement”) relating to shares of common stock, par value $0.01 per share (the “Common Stock”), of FreightCar America, Inc., a Delaware corporation (the “Issuer”). Item 3, Item 4, Item 5 and Item 6 of the Statement are hereby amended and supplemented as set forth below. Capitalized terms used in this Amendment No. 7 and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 is hereby supplemented by adding the following additional information:
As previously disclosed, on March 23, 2023, the Issuer and OC III LFE entered into the Purchase Agreement. The conditions to closing of the Purchase Agreement were satisfied and May 22, 2023 and the Closing occurred on that date. At the Closing, OC III LFE acquired 85,412 shares of Series C Preferred Stock of the Issuer and warrants for 1,636,313 shares of Common Stock (the “March 2023 Warrant”). Such warrants have an exercise price of $3.57 per share, are exercisable at any time and expire on May 22, 2033.
The foregoing descriptions of the March 2023 Warrant does not purport to be complete and is qualified in its entirety by reference to the full text of the March 2023 Warrant, attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 5. Interest in Securities of the Issuer.
Item 5(c) is hereby supplemented by adding the following additional information:
(c) The disclosure set forth in Item 3 and Item 6 of this Amendment No. 7 is incorporated herein by reference. Except as set forth herein, there have been no transactions with respect to the Common Stock during the sixty days prior to the date of this Amendment No. 7 by the Reporting Person or, to its knowledge, by any executive officer or director of the Reporting Person.
Item 6. Contracts, Arrangements, Understandings, or Relationships with Respect to Securities of the Issuer.
Item 6 is hereby supplemented by adding the following additional information:
Amendment No. 2 to the Reimbursement Agreement
In connection with the closing of the transactions contemplated by the Purchase Agreement, the Issuer entered into Amendment No. 2 to the Reimbursement Agreement (“Amendment No. 2”) with the Loan Parties (as defined therein), CO Finance LVS VI LLC (the “LC Provider”), and U.S. Bank, National Association, as disbursing agent and collateral agent. Amendment No. 2 amends and sets forth the terms of the Issuer’s continuing obligations to the LC Provider in connection with the outstanding standby letter of credit issued by Wells Fargo Bank, N.A., in the principal amount of $25.0 million for the account of the Issuer and for the benefit of Siena Lending Group LLC.
The foregoing description of Amendment No. 2 to the Amended and Restated Reimbursement Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of Amendment No. 2 to the Amended and Restated Reimbursement Agreement, attached hereto as Exhibit 99.2 and incorporated herein by reference.